Eloxx Pharmaceuticals, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023; unaudited. Eloxx is a clinical-stage biopharmaceutical company developing ribosome-modulating drug candidates for rare genetic diseases and cancers. It has no approved products and reported no product revenue.
Financial performance and position
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $3.5 million | $7.9 million; down 56% |
| General and administrative expense | $2.0 million | $3.1 million; down 35% |
| Total operating expenses / operating loss | $5.5 million / ($5.5 million) | $11.0 million / ($11.0 million) |
| Other expense, net | $0.7 million | $0.7 million |
| Net loss | $6.2 million | $11.6 million; loss narrowed 46% |
| Net loss per share, basic and diluted | ($2.88) | ($5.36) |
| Net cash used in operating activities | $6.8 million | $9.5 million |
Margins are not meaningful because the company had no revenue. Lower R&D costs mainly reflected reduced preclinical work on inhaled ELX-02 for cystic fibrosis, lower cystic-fibrosis trial activity funded by the Cystic Fibrosis Foundation (CFF), and lower personnel costs. Lower G&A reflected reduced personnel, professional fees, and stock-based compensation.
At March 31, 2023, cash and cash equivalents were $4.9 million (restricted cash: $0.3 million), versus $19.2 million and $0.3 million, respectively, at year-end 2022. Total assets were $7.2 million; total liabilities were $23.5 million; stockholders’ deficit was $16.3 million. Accumulated deficit was $280.6 million. Debt principal outstanding was $5.0 million, with a $4.7 million carrying value before classification between current and long-term portions. The Hercules loan bears a 14.25% stated rate at quarter-end; its effective rate was 18.9%. The balance-sheet current portion of debt was $1.5 million and long-term debt was $4.0 million.
Cash, cash equivalents, and restricted cash decreased by $14.3 million during the quarter. Operating activities used $6.8 million; financing activities used $7.5 million, primarily for Hercules principal repayment; investing activities provided $0.01 million. No profitability or revenue guidance was provided.
Material changes and notable items
- On March 7, 2023, Eloxx amended its Hercules loan, repaid $7.5 million of principal, extended the interest-only period through September 1, 2023, and lowered the minimum qualified cash covenant from $10.0 million to $2.25 million. Principal payments on the remaining balance are scheduled to begin September 1, 2023; maturity is April 1, 2025. The amendment generated a $0.4 million debt-extinguishment loss.
- R&D and G&A spending fell substantially year over year, reducing the quarterly net loss, while cash fell sharply from year-end after the debt repayment and continued operating burn.
- The CFF discontinued funding the ELX-02 cystic-fibrosis program in September 2022; the remaining $7.4 million under its amended award is unavailable under the current program. Cumulative CFF advances recorded as liabilities were $12.5 million at quarter-end.
- In September 2022, Eloxx paused ELX-02 development in cystic fibrosis after the Phase 2 combination study with ivacaftor did not meet statistical significance on efficacy endpoints. The lead clinical focus is ELX-02 for Alport syndrome.
Outlook, risks, and contingencies
- Going concern: Management said quarter-end cash is insufficient to fund current and planned operations for at least 12 months after filing. Recurring losses and financing uncertainty raise substantial doubt about the company’s ability to continue as a going concern. Additional financing is needed; no assurance it will be available. Without funding, Eloxx may reduce or defer expenses, delay or discontinue programs, or license rights it would otherwise retain.
- Funding and debt: The filing’s risk summary says substantial additional funding is needed by September 2023. An additional $10.0 million Hercules tranche was subject to lender investment-committee approval and timing conditions; it was not assured. Covenant compliance was reported at March 31, but management cautioned that future compliance could be affected by liquidity constraints. Failure to comply without a waiver could accelerate repayment.
- Clinical development: The Alport Phase 2 trial was targeting up to eight patients with nonsense mutations, with two months of dosing and three months of follow-up; topline results were expected in the first half of 2023. On May 2, 2023, after quarter-end, the FDA cleared the ZKN-013 IND for a single-ascending-dose trial in healthy volunteers for potential RDEB treatment. These are development expectations, not outcomes reported in this quarter.
- Nasdaq listing: Nasdaq notified Eloxx on April 11, 2023 that it had not regained compliance with the $35 million minimum market-value requirement. The company appealed on April 18; a hearing was scheduled for May 18, 2023. Continued listing was uncertain.
- Other risks and contingencies: Drug-development failure, adverse events, regulatory delays, patient recruitment, financing dilution, intellectual-property challenges, and reliance on third parties are material risks. The company reported no material pending legal proceedings. It also disclosed that cash deposits exceeded insured limits, with no significant impact reported to date.
Key facts for investors to verify
- Whether Eloxx secured financing sufficient to fund operations beyond the disclosed short runway, and whether subsequent filings update its going-concern assessment.
- Outcomes of the Alport trial and ZKN-013 clinical progress, including timing, enrollment, safety, and efficacy data.
- Nasdaq Hearings Panel’s decision and the company’s subsequent listing status.
- Current Hercules loan balance, covenant headroom, scheduled repayments, and any access to additional loan tranches.
- Whether any future CFF funding, strategic collaboration, or equity issuance changes liquidity, program scope, or shareholder dilution.